Company intelligence / Profile preview

ReEngage Therapeutics

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Preclinical ACSS2 inhibitors show benefits in patient-derived xenograft models for multiple cancers, including single-agent activity in colorectal and triple negative breast cancers, and combinations with platinum in gastric, ovarian, and NSCLC. Clinical candidate MTB-9655 completed Phase 1 dose-escalation.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

EpiVario, Inc. (in-licensed compounds)

Beyond the preview

Go deeper on ReEngage Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReEngage Therapeutics.

Explore the full profile